Phase 3 (Top-line Data)
Amp Volatility Score
Catalyst Info & Data Links
TITLE: VLA1553 for Chikungunya - Phase 3 Top-line Data
Phase 3 - ClinicalTrial.gov (NCT04546724) Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
Phase 1 - ClinicalTrial.gov (NCT03382964) Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers
WHAT IS THE NEXT CATALYST EVENT?
Phase 3 Top-line Data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Q1 2021 (see slide 21)
2020: Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. The Lancet Infectious Diseases.
2017: Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. JCI insight, 2(6).
MECHANISM OF ACTION / RATIONALE
VLA1553 is a monovalent, single dose, live-attenuated vaccine candidate against chikungunya (learn more HERE).
Updated by HC
VLA, VLA1553, Chikungunya, vaccine,
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post